Evaluations Between PBSC Treatment Cycles : 
GTI0101 (04/08/93) 
Page 21 of 35 
For patients completing each PBSC cycle, the following evaluations will be done 1 month 
after patient is discharged and repeated monthly until the next cycle begins. See section 
4.4 if patient is completely done with all of the study therapy or has completed at least 
1 cycle (and has subsequently discontinued): 
4.31 Objective signs and symptoms : Vital signs (blood pressure, pulse, temperature 
and respirations) weight and height . 
4.32 Physical Examination : Target physical exam 
4.33 Kamofskv Performance Status (see Appendix IV). 
4.34 Urinalysis : Routine screening urinalysis including creatinine and creatinine 
clearance. 
4.35 Serum Chemistries : include uric acid, calcium, phosphorus, magnesium, amylase 
transaminases (SGOT, SGPT), alkaline phosphatase, LDH, total bilirubin, 
triglycerides, BUN, creatinine, albumin, total protein, electrolytes, and glucose. 
4.36 Hematology : Complete blood count (CBC), differential, platelets, and 
coagulation tests should include PT (Prothrombin Time), PTT (Partial 
Thromboplastin Time), and fibrinogen. 
4.37 Pregnancy Test : Serum pregnancy test will be repeated monthly during the first 
year. 
4.38 Liver-Spleen Size : Optional: based on clinical assessment. 
4.39 Glucocerebrosidase enzvme level determination : Collect PBMCs. 
4.310 Antibody Analysis : Serum sample for anti-retroviral antibodies. 
4.311 Freezing Specimens : Additional serum, plasma, and cells should be separated 
and frozen. 
4.312 DNA/RNA Analysis : Circulating mononuclear cells will be analyzed using PCR- 
related techniques for the presence of vector gene sequences. 
Recombinant DNA Research, Volume 17 
